DAX24.304 -0,1%ESt505.430 +0,4%Top 10 Crypto13,88 +2,4%Dow42.763 +1,1%Nas19.530 +1,2%Bitcoin92.069 +0,5%Euro1,1399 ±0,0%Öl66,65 +2,1%Gold3.311 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 RENK RENK73 NVIDIA 918422 HENSOLDT HAG000 Lufthansa 823212 Bayer BAY001 Palantir A2QA4J Siemens Energy ENER6Y BYD A0M4W9 Commerzbank CBK100 Novo Nordisk A3EU6F Infineon 623100 BASF BASF11 BioNTech (ADRs) A2PSR2
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Arbeitsmarkt im Fokus: DAX geht etwas schwächer ins Wochenende -- Wall Street mit Zuwächsen -- Spionage-Vorwürfe & Co. verunsichern Palantir-Anleger -- Broadcom enttäuscht -- Tesla, VW im Fokus
Top News
Das sind die aktuellen Preise von Öl, Erdgas & Co. Das sind die aktuellen Preise von Öl, Erdgas & Co.
So bewegen sich die Kurse von Bitcoin, Ripple, Bitcoin Cash und Ethereum am Samstagvormittag So bewegen sich die Kurse von Bitcoin, Ripple, Bitcoin Cash und Ethereum am Samstagvormittag
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

AbbVie Aktie

Handeln
AbbVie Aktien-Sparplan
165,20 EUR +0,60 EUR +0,36 %
FSE
189,91 USD +0,11 USD +0,06 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.290,51 Mrd. EUR

KGV74,34Div. Rendite3,54%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireAbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 ...
PR NewswireU.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
PR NewswireAbbVie Announces Provincial Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia in Québec
PR NewswireAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
PR NewswireAbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year
PR NewswireAbbVie to Host First-Quarter 2023 Earnings Conference Call
PR NewswireCoolSculpting® Elite Announces First Ever CoolMonth
PR NewswireAllergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireAbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
PR NewswireRisankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
PR NewswireAbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
PR NewswireAbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor T...
PR NewswireAbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema
PR NewswireAbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting
PR NewswireAbbVie to Present at the Barclays Global Healthcare Conference
PR NewswireAbbVie to Present at the Cowen 43rd Annual Health Care Conference
PR NewswireAbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)
PR NewswireAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
PR NewswireAbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
PR NewswireAbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
PR NewswireAllergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
PR NewswireJUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE
PR NewswireSkinMedica® Launches Even & Correct
PR NewswireAbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
PR NewswireQULIPTA™ Now Approved by Health Canada for the Preventive Treatment of Episodic Migraine in Adults
PR NewswireAbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
PR NewswireAbbVie to Host Fourth-Quarter 2022 Earnings Conference Call
PR NewswireAbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR NewswireU.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder
PR NewswireAbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year
PR NewswireAbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
PR NewswireAbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients
PR NewswireAbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science
PR NewswireAbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
PR NewswireAbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress
PR NewswireAbbVie Announces Provincial Reimbursement for RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.